Galecto Biotech Ab

Galecto Biotech AB is a biotechnology company that focuses on the discovery and development of novel therapeutics for fibrosis and cancer. The company's mission is to improve the lives of patients suffering from these diseases through the development of innovative and effective treatments. Galecto Biotech AB's research and development efforts are primarily focused on small molecule inhibitors targeting galectin proteins, which play a key role in fibrosis and cancer progression. By targeting these proteins, Galecto aims to develop potent and selective drugs that can modulate the disease processes and provide meaningful clinical benefits to patients. For more information about Galecto Biotech AB and its ongoing research programs, please visit their website.